Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Lyell Immunopharma, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PINACLE - H2H WILL EVALUATE RONDECABTAGENE AUTOLEUCEL (RONDE-CEL) VERSUS INVESTIGATOR'S CHOICE OF APPROVED CD19 CAR T-CELL THERAPIES IN PATIENTS WITH AGGRESSIVE LARGE B-CELL LYMPHOMA RECEIVING TREATMENT IN THE SECOND LINE (2L) SETTING RONDE-CEL IS LYELL'S NEXT-GENERATION, DUAL-TARGETING CD19/CD20 CAR T-CELL THERAPY DESIGNED TO DELIVER IMPROVED COMPLETE RESPONSE RATES AND LONGER DURATION OF RESPONSES OVER CURRENTLY APPROVED CD19 CAR T-CELL THERAPIES STEERING COMMITTEE OF DISTINGUISHED LYMPHOMA EXPERTS ESTABLISHED TO ADVISE ON THE DESIGN AND CONDUCT OF THIS FIRST-OF-ITS-KIND CAR T-CELL CLINICAL TRIAL SOUTH SAN FRANCISCO, CALIF., SEPT. 03, 2025 (GLOBE NEWSWIRE) -- LYELL IMMUNOPHARMA, INC. (NASDAQ: LYEL), A LATE-STAGE CLINICAL COMPANY ADVANCING NEXT-GENERATION CAR T-CELL THERAPIES FOR PATIENTS WITH CANCER, TODAY ANNOUNCED THE INITIATION OF PINACLE - H2H, A PHASE 3 HEAD-TO-HEAD CAR T-CELL THERAPY RANDOMIZED CONTROLLED TRIAL AND THE FORMATION OF A STEERING COMMITTEE OF PREEMINENT LYMPHOMA EXPERTS.

LYELL IMMUNOPHARMA ANNOUNCES THE INITIATION OF A PHASE 3 HEAD-TO-HEAD CAR T-CELL THERAPY CLINICAL TRIAL IN AGGRESSIVE LARGE B-CELL LYMPHOMA AND FORMATION OF EXPERT STEERING COMMITTEE

SOUTH SAN FRANCISCO, CALIF., SEPT. 02, 2025 (GLOBE NEWSWIRE) -- LYELL IMMUNOPHARMA, INC. (NASDAQ: LYEL), LYELL IMMUNOPHARMA, INC. (NASDAQ: LYEL), A LATE-STAGE CLINICAL COMPANY ADVANCING NEXT-GENERATION CAR T-CELL THERAPIES FOR PATIENTS WITH CANCER, ANNOUNCED TODAY THAT MEMBERS OF ITS SENIOR MANAGEMENT TEAM WILL PRESENT AND PARTICIPATE IN THE FOLLOWING INVESTOR CONFERENCES: MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE ON MONDAY, SEPTEMBER 8THAT 9:15 AM EASTERN TIME H.C.

LYELL IMMUNOPHARMA ANNOUNCES PARTICIPATION IN SEPTEMBER INVESTOR CONFERENCES

SOUTH SAN FRANCISCO, CALIF., AUG. 12, 2025 (GLOBE NEWSWIRE) -- LYELL IMMUNOPHARMA, INC. (NASDAQ: LYEL), A LATE-STAGE CLINICAL COMPANY ADVANCING NEXT-GENERATION CAR T-CELL THERAPIES FOR PATIENTS WITH CANCER, TODAY REPORTED FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS FOR THE SECOND QUARTER ENDED JUNE30, 2025. LYELL'S LEAD CLINICAL PROGRAM, LYL314, IS A NEXT-GENERATION AUTOLOGOUS DUAL-TARGETING CD19/CD20 CAR T-CELL PRODUCT CANDIDATE UNDER EVALUATION IN PINACLE, A SINGLE-ARM PIVOTAL TRIAL ENROLLING PATIENTS WITH RELAPSED AND/OR REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL) IN THE 3L+ SETTING AND IN A PHASE 1/2 STUDY IN THE 2L SETTING.

LYELL IMMUNOPHARMA REPORTS BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS FOR THE SECOND QUARTER 2025

SOUTH SAN FRANCISCO, CALIF., JULY 25, 2025 (GLOBE NEWSWIRE) -- LYELL IMMUNOPHARMA, INC. (NASDAQ: LYEL), A CLINICAL-STAGE COMPANY ADVANCING NEXT-GENERATION CAR T-CELL THERAPIES FOR PATIENTS WITH CANCER, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A SECURITIES PURCHASE AGREEMENT FOR A PRIVATE PLACEMENT WITH CERTAIN INSTITUTIONAL AND OTHER ACCREDITED INVESTORS, FOR GROSS PROCEEDS OF UP TO APPROXIMATELY $100 MILLION.

LYELL IMMUNOPHARMA ANNOUNCES UP TO $100 MILLION EQUITY PRIVATE PLACEMENT

SOUTH SAN FRANCISCO, CALIF., JUNE 23, 2025 (GLOBE NEWSWIRE) -- LYELL IMMUNOPHARMA, INC. (NASDAQ: LYEL), A CLINICAL-STAGE COMPANY ADVANCING NEXT-GENERATION CAR T-CELL THERAPIES FOR PATIENTS WITH CANCER, ANNOUNCED TODAY THAT MEMBERS OF ITS SENIOR MANAGEMENT TEAM WILL PARTICIPATE IN THE H.C. WAINWRIGHT HCW@HOME SERIES TAKING PLACE VIRTUALLY ON WEDNESDAY, JUNE 25, 2025, AT 12:00 PM ET.

LYELL IMMUNOPHARMA TO PARTICIPATE IN THE H.C. WAINWRIGHT HCW@HOME SERIES

SOUTH SAN FRANCISCO, CALIF., JUNE 17, 2025 (GLOBE NEWSWIRE) -- LYELL IMMUNOPHARMA, INC. (NASDAQ: LYEL), A CLINICAL-STAGE COMPANY ADVANCING NEXT-GENERATION CAR T-CELL THERAPIES FOR PATIENTS WITH CANCER, TODAY ANNOUNCED POSITIVE NEW CLINICAL DATA FROM THE MULTI-CENTER PHASE 1/2 TRIAL OF LYL314, INCLUDING DATA FROM PATIENTS WITH LARGE B-CELL LYMPHOMA (LBCL) TREATED IN THE THIRD- OR LATER-LINE (3L+) SETTING. LYL314 IS AN AUTOLOGOUS DUAL-TARGETING CD19/CD20 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL PRODUCT CANDIDATE WITH REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) AND FAST TRACK DESIGNATIONS FROM THE FDA THAT IS IN DEVELOPMENT FOR PATIENTS WITH RELAPSED AND/OR REFRACTORY (R/R) LBCL. IN PATIENTS TREATED IN THE 3L+ SETTING (N = 25), LYL314 CONTINUED TO DEMONSTRATE ROBUST CLINICAL RESPONSES, WITH AN 88% OVERALL RESPONSE RATE AND A 72% COMPLETE RESPONSE RATE. OF THE 3L+ PATIENTS WHO ACHIEVED A COMPLETE RESPONSE, 71% REMAINED IN COMPLETE RESPONSE AT  6 MONTHS. THE SINGLE-ARM PIVOTAL PINACLE TRIAL, A SEAMLESS EXPANSION OF THE PHASE 1/2 TRIAL OF PATIENTS WITH R/R LBCL BEING TREATED IN THE 3L+ SETTING, IS UNDERWAY.

LYELL IMMUNOPHARMA ANNOUNCES POSITIVE NEW CLINICAL DATA DEMONSTRATING HIGH RATES OF DURABLE COMPLETE RESPONSES FROM THE PHASE 1/2 TRIAL OF LYL314 FOR THE TREATMENT OF AGGRESSIVE LARGE B-CELL LYMPHOMA

SOUTH SAN FRANCISCO, CALIF., JUNE 09, 2025 (GLOBE NEWSWIRE) -- LYELL IMMUNOPHARMA, INC. (NASDAQ: LYEL), A CLINICAL-STAGE COMPANY ADVANCING A PIPELINE OF NEXT-GENERATION CAR T-CELL THERAPIES FOR PATIENTS WITH CANCER, TODAY ANNOUNCED THE APPOINTMENT OF MARK J. BACHLEDA, PHARMD, MBA AS AN INDEPENDENT MEMBER OF THE BOARD OF DIRECTORS, DAVID SHOOK, MD AS CHIEF MEDICAL OFFICER, AND MARK MELTZ, JD AS GENERAL COUNSEL AND CORPORATE SECRETARY. THESE APPOINTMENTS, ALONG WITH THE APPOINTMENT EARLIER IN THE YEAR OF JARRAD AGUIRRE, MD, MBA AS SENIOR VICE PRESIDENT, MEDICAL AFFAIRS, FURTHER STRENGTHEN THE COMPANY'S CLINICAL AND COMMERCIAL CAPABILITIES.

LYELL IMMUNOPHARMA STRENGTHENS CLINICAL AND COMMERCIAL CAPABILITIES WITH KEY BOARD AND EXECUTIVE APPOINTMENTS

SOUTH SAN FRANCISCO, CALIF., JUNE 04, 2025 (GLOBE NEWSWIRE) -- LYELL IMMUNOPHARMA, INC. (NASDAQ: LYEL), A CLINICAL-STAGE COMPANY ADVANCING A PIPELINE OF NEXT-GENERATION CAR T-CELL THERAPIES FOR PATIENTS WITH CANCER, ANNOUNCED TODAY THAT MEMBERS OF ITS SENIOR MANAGEMENT TEAM WILL PRESENT AND PARTICIPATE IN THE GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE ON WEDNESDAY, JUNE 11TH AT 10:00 AM ET.

LYELL IMMUNOPHARMA TO PARTICIPATE IN THE GOLDMAN SACHS GLOBAL HEALTHCARE CONFERENCE

SOUTH SAN FRANCISCO, CALIF., MAY 13, 2025 (GLOBE NEWSWIRE) -- LYELL IMMUNOPHARMA, INC. (NASDAQ: LYEL), A CLINICAL-STAGE COMPANY ADVANCING A PIPELINE OF NEXT-GENERATION CAR T-CELL THERAPIES FOR PATIENTS WITH CANCER, TODAY REPORTED FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS FOR THE FIRST QUARTER ENDED MARCH31, 2025. LYELL'S LEAD CLINICAL PROGRAM, LYL314 (FORMERLY KNOWN AS IMPT-314), IS AN AUTOLOGOUS CD19/CD20 DUAL-TARGETING CAR T-CELL PRODUCT CANDIDATE UNDER EVALUATION IN A PHASE 1/2 TRIAL ENROLLING PATIENTS WITH RELAPSED AND/OR REFRACTORY LARGE B-CELL LYMPHOMA (LBCL). LYL314 WAS RECENTLY GRANTED RMAT DESIGNATION BY THE UNITED STATES FDA IN RECOGNITION OF ITS POTENTIAL TO ADDRESS SIGNIFICANT UNMET NEEDS IN PATIENTS WITH AGGRESSIVE LBCL IN THE THIRD- OR LATER-LINE SETTING.

LYELL IMMUNOPHARMA REPORTS BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS FOR THE FIRST QUARTER 2025

SOUTH SAN FRANCISCO, CALIF., MAY 01, 2025 (GLOBE NEWSWIRE) -- LYELL IMMUNOPHARMA, INC. (NASDAQ: LYEL), A CLINICAL-STAGE COMPANY ADVANCING A PIPELINE OF NEXT-GENERATION CAR T-CELL THERAPIES FOR PATIENTS WITH CANCER, TODAY ANNOUNCED THAT AN ABSTRACT HIGHLIGHTING NEW CLINICAL DATA FROM THE PHASE 1/2 TRIAL OF LYL314 (FORMERLY IMPT-314) IN LARGE B-CELL LYMPHOMA WILL BE PRESENTED AS AN ORAL PRESENTATION AT THE INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA (ICML) 2025 TAKING PLACE IN LUGANO, SWITZERLAND JUNE 17-21, 2025.

LYELL IMMUNOPHARMA ANNOUNCES ORAL PRESENTATION OF NEW CLINICAL DATA FROM THE PHASE 1/2 TRIAL OF LYL314 FOR THE TREATMENT OF LARGE B-CELL LYMPHOMA AT THE INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA (ICML) 2025

Lyell Immunopharma, Inc.

LYEL

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Lyell Immunopharma, Inc.

LYEL.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

LYEL